Science

Articles

• Vect-Horus and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)
  28 January 2019, by Jonathan NOWAK

  and publish a review article on CNS drug delivery (Vlieghe and Khrestchatisky, 2012, Med Res Rev).

• Our latest research article is now available on bioRxiv and medRxiv
  11 July 2025, by Emmanuelle BETTENDORF

  In this study, we explored the identification and optimization of cross-species reactive VHHs (single-domain antibodies from camelids) targeting the transferrin receptor 1 (TfR1) — a promising strategy for delivering therapeutics across the blood-brain barrier.
  We focused on two candidates, C5 and B8, which bind TfR1 in rodents, non-human primates, and humans. These VHHs show potential as molecular shuttles for transporting imaging or therapeutic agents across species — paving the way for (…)

• Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
  28 January 2019, by Jonathan NOWAK

  Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
  Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
  http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)

• 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
  12 April 2022, by Elodie DORMES

  Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.

• TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
  31 October 2019, by Elodie DORMES

  Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.

• Festival of Biologics 2019 in BASEL
  31 October 2019, by Elodie DORMES

  Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».

• Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
  28 January 2019, by Jonathan NOWAK

  (Molino et al., 2017, The FASEB Journal)
  www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

• TIDES Europe, Nov. 11-13, 2020 - 100% Virtual
  12 November 2020, by Elodie DORMES

  Dr Guillaume JACQUOT will share a presentation on “TfR-targeting VHH Nanobodies for Extra-hepatic Delivery of Oligonucleotides” a good opportunity for Vect-Horus to present its last results.
  A live Q&A session will also give the opportunity to ask questions on last trends and highlights in Oligonucleotide & Peptide Therapeutics field to expert panelists.
  TIDE is the Europe’s #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate new (…)

• AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
  28 January 2019, by Jonathan NOWAK

  Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832

• Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!
  8 September 2023, by Emmanuelle BETTENDORF

  On this occasion, our partner Radiomedix, Inc. , was selected to present an update of our joint research program. This talk untitled “Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein Receptors (LDLR)” will be given Sunday, September 10th between 4:55 PM and 5:05 PM at the Hall E2 by Izabela Tworowska.
  Come and take the opportunity to meet and discuss with Vect-Horus on September 9-13, 2023 in Vienna!
  Our #Oncology team, Cedric (…)